NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
Revenue of NovoCure Limited (NVCR)
Revenue in 2023 (TTM): $509.34 M
According to NovoCure Limited's latest financial reports the company's current revenue (TTM) is $509.34 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of NovoCure Limited
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $509.34 M | $381.06 M | $-175,865,000 | $-191,740,000 | $-207,043,000 |
| 2022 | $537.84 M | $422.97 M | $-63,109,000 | $-81,846,000 | $-92,534,000 |
| 2021 | $535.03 M | $420.15 M | $-38,384,000 | $-52,075,000 | $-58,351,000 |
| 2020 | $494.37 M | $387.87 M | $45.3 M | $18.1 M | $19.81 M |
| 2019 | $351.32 M | $262.71 M | $14.21 M | $-8,824,000 | $-7,230,000 |
| 2018 | $248.07 M | $168.02 M | $-23,445,000 | $-45,942,000 | $-63,559,000 |
| 2017 | $177.03 M | $121.42 M | $-29,127,000 | $-48,497,000 | $-61,662,000 |
| 2016 | $82.89 M | $36.61 M | $-108,890,000 | $-121,464,000 | $-131,845,000 |
| 2015 | $33.09 M | $12.48 M | $-101,115,000 | $-107,147,000 | $-111,581,000 |
| 2014 | $15.49 M | $5.45 M | $-78,193,000 | $-80,300,000 | $-80,682,000 |
| 2013 | $10.36 M | $3.35 M | $-63,133,000 | $-77,017,000 | $-77,370,000 |